Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog® Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog® (insulin aspart [rDNA origin] injection) are invited to visit www.novolog.com and tell us how they’re giving back to their local communities.
Now through March 15, NovoLog® patients can submit their story and photo online for the chance to be crowned a NovoLog® Community Star. Finalists will be selected by a panel of judges, and each will receive a $5,000 donation to a local diabetes-related organization of their choice. One grand prize winner will also receive a one-year online subscription to Weight Watchers® to help with their diabetes management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59947-novo-nordisk-first-novolog-community-star-contest-type-2-diabetes-patients
Blood is an essential component for life, but many people do not think about it until the need is critical. Each year 234 million major operations are performed worldwide, many involving blood transfusions or treatments resulting in a continuous need for donations.
That’s why Abbott (NYSE: ABT) and Real Madrid soccer star Cristiano Ronaldo are partnering to bring even more attention to this important cause. Regarded as one of the top soccer players in the world, Ronaldo will serve as the first global ambassador for the BE THE 1™ movement – developed to inspire young people around the world to regularly donate blood.
“We can all make a difference by donating blood. Each donation can benefit up to three people in emergency situations and for long-term medical treatments,” said Cristiano Ronaldo, forward for Real Madrid and Captain for Portugal National Football. “That’s why I am enthusiastic to be partnering with Abbott to bring awareness to the importance of blood donation and to encourage people around the world to become lifelong blood donors and help save lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7668251-abbott-cristiano-ronaldo-donate-blood/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
One of the first steps to take when you have decided that you want to do something about your health is to do a colon and blood cleanse.
Hi Rudy, Again,
Not only should you do this cleanse to improve your health, but when you fall ill to any disease as simple as constant mucus flow, skin eruptions, or to a deadly disease such as cancer.
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
As sleaze oozes from the Pentagon, banished Marine and Naval Academy alum Susanna Marcasi finds a web of corruption and must take on a man to whom all are beholden, Defense Secretary Manfred Stahl. Can she bring down the cloistered power brokers deep within the military’s superstructure and survive? Blood Stripe: The Susanna Marcasi Chronicles Find out more at – http://www.GinaMariaDiNicolo.com
As sleaze oozes from the Pentagon,
banished Marine and Naval Academy alum Susanna Marcasi finds a web of
corruption and must take on a man to whom all are beholden, Defense
Secretary Manfred Stahl. Can she bring down the cloistered power
brokers deep within the military’s superstructure and survive? Blood
Stripe: The Susanna Marcasi Chronicles. Find out more at:
http://www.GinaMariaDiNicolo.com or on Amazon at:
http://j.mp/Blood-Stripe Cincinnati City Beat and
Amazon reviewer John Kelly says “Like a literary version of ‘A Few Good
Men (and Women)’ on steroids, Gina Maria DiNicolo rips into your
emotional core like a ‘kill shot’ from page one and never lets up for
322 pages. This book, not for the weak of heart, tells the story of
strength, courage and no mercy in the most elite units of the U.S.
Armed Forces.” Baltimore native Gina Maria DiNicolo graduated
from the U.S. Naval Academy with a degree in history and an attraction
to the unconventional. She accepted a commission in the U.S. Marine
Corps where she worked in aviation, recruiting, history, and public
affairs. As a fulltime author and historian, in addition to her two
books, DiNicolo has written scores of articles for the Military Officer
Magazine and other publications. After publishing Blood Stripe, she
sought to get her historian game on and accepted a one-year, work/study
assignment as a senior editor for the U.S. Army Center of Military
History in Washington, D.C., producing studies on military operations
in Iraq and Afghanistan. She is a dancer specializing in Argentine
Tango. For a review copy of Blood Stripe: The Susanna
Marcasi Chronicles or to arrange an interview with Gina Maria
DiNicolo contact Scott Lorenz of Westwind Communications Book
Marketing http://www.book-marketing-expert.com/ or by phone
734-667-2090.
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Twone C. brings that
Dallas sound to represent everyone who needs to move on and make their
own spot at the top. Twone C. and TwistinandShakin mix together
influences from the East Coast, West Coast and the Big D to keep the
blood pumping so strong. #GhostwritingProductions #TWISTINANDSHAKIN
@JayLuck214 #DallasMusic #GodIsGreat #TheMexiking
